ENvue Medical, Inc
0.37
USD
+0.02
(+4.36%)
CIK
1326706
ISIN
US63008J8760
CUSIP
63008J876
Return %
Stock
S&P 500
1Y
-99.47
14.20
3Y
-99.97
81.12
5Y
-100.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Doron Robert Besser
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Tyler United States
- CIK
- 0001326706
- Website
- envuemed.com
- Similar Companies
- Business
- ENvue Medical, Inc. is a commercial-stage medical technology company that develops, manufactures, and commercializes non-invasive medical devices and navigation systems for enteral nutrition access and therapeutic acoustic medicine. Founded in 2003 and headquartered in Tyler, Texas, with research and development operations in Nesher, Israel, the company serves hospitals, critical care units, long-term care facilities, and home healthcare settings across North America and select international markets. ENvue Medical operates primarily across two business segments: Enteral Access Navigation and Surface Acoustic Wave (SAW) Therapeutics. The company's core product offerings comprise the ENvue Navigation System, an FDA 510(k)-cleared electromagnetic guidance platform designed for real-time, radiation-free bedside placement of enteral feeding tubes into the stomach or small bowel; ENvue Drive, a robotic-assisted feeding tube placement platform incorporating proprietary Ask Oscar artificial intelligence navigation software to deliver automated guidance, trajectory correction, and mechanical tube propulsion; UroShield, an external clip-on therapeutic ultrasound device utilizing low-frequency acoustic waves to disrupt biofilm formation, reduce bacterial colonization, and prevent catheter-associated urinary tract infections (CAUTIs); PainShield, a wearable, patch-based ultrasound therapy device providing localized acoustic energy for chronic pain management, musculoskeletal rehabilitation, and nerve repair; and WoundShield, a portable low-intensity ultrasound system designed to accelerate tissue regeneration and promote the healing of chronic wounds. In recent strategic developments, the company acquired ENvue Medical Holdings, Corp. via a stock-for-stock merger in February 2025, subsequently rebranding from NanoVibronix, Inc. to ENvue Medical, Inc. in December 2025 to reflect its focused commitment to enteral feeding technology. Following the merger, Dr. Doron Besser assumed the role of Chief Executive Officer to steer commercial expansion. In July 2026, the company advanced its enteral access technology with the introduction of the ENvue Drive robotic prototype, and in September 2026, its common stock transitioned to trading on the OTC Markets under the ticker symbol FEED.